stella
Parkinson's DiseaseAugust 2026Summary reviewed July 2026

A Daily Pill Gave Early Parkinson's Patients 9 More Points of Movement Improvement

Researchers tested tavapadon, a once-daily pill, in 304 people with early Parkinson's disease. After 26 weeks, those taking tavapadon had significantly better movement and daily function scores compared to those on a sugar pill, with side effects mainly including nausea, headache, and dizziness.

What the trial was testing

The TEMPO-2 enrolled 304 patients with parkinson's disease. The study was sponsored by AbbVie and tracked outcomes across the full group of patients who matched the trial's eligibility profile.

It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.

What the results showed

Tavapadon improved Parkinson's symptoms by 9 points more than placebo on a standard movement scale.

The Lancet. Neurology · 2026 · NCT04223193

These findings — that tavapadon improved movement and daily activities more than placebo on a standard Parkinson's scale — were published in the The Lancet. Neurology and represent the headline result of the study.

Researchers tracked outcomes across 304 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.

What this means for patients

For patients with parkinson's disease, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.

What you can do now

This was a large-scale study and tavapadon showed meaningful benefits for early Parkinson's. The drug is not yet FDA-approved—it's still being studied for long-term safety. If you have early Parkinson's, talk to your doctor about available treatments and whether this approach might become an option in the future.

Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.

Open parkinson's disease trials

RecruitingTesting effectiveness

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo. The study will last about 14 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neither the participants nor the study staff will know which treatment is given. The study includes a screening period, a 4-week period during which Parkinson's medications must remain stable, and a 12-week treatment period. During the treatment period, limited adjustments to levodopa are allowed if needed.

Little Rock, Arkansas, United States +24 more
RecruitingObservational study

The Role of Priors in Hallucinatory Perception in Parkinson's Disease

The goal of this observational study is to better understand the mechanisms of hallucinations in patients with Parkinson's disease. The main question it aims to answer is: Do prior expectations increase the rate of false perceptions during a visual stimulus detection task more in Parkinson's disease patients with visual hallucinations compared to those without? Participants will undertake a computer task involving face detection and a battery of neuropsychological tests.

Grenoble, France +1 more